These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11207005)

  • 41. Serum thyroglobulin levels after thyroxine withdrawal in patients with low risk papillary thyroid carcinoma.
    Sisson JC; Thompson NW; Giordano TJ; England BG; Normolle DP
    Thyroid; 2000 Feb; 10(2):165-9. PubMed ID: 10718554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful?
    Ibrahimpasic T; Ghossein R; Carlson DL; Nixon IJ; Palmer FL; Patel SG; Tuttle RM; Shaha A; Shah JP; Ganly I
    Ann Surg Oncol; 2015 Dec; 22(13):4193-7. PubMed ID: 25893415
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission.
    Fugazzola L; Mihalich A; Persani L; Cerutti N; Reina M; Bonomi M; Ponti E; Mannavola D; Giammona E; Vannucchi G; di Blasio AM; Beck-Peccoz P
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3201-8. PubMed ID: 12107225
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk of malignancy in follicular thyroid neoplasm: predictive value of thyrotropin.
    Zimny M; Selkinski I; Blasius S; Rink T; Schroth HJ; Grünwald F
    Nuklearmedizin; 2012; 51(4):119-24. PubMed ID: 22526481
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis.
    Kim KW; Park YJ; Kim EH; Park SY; Park DJ; Ahn SH; Park DJ; Jang HC; Cho BY
    Head Neck; 2011 May; 33(5):691-5. PubMed ID: 21484918
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blood thyroglobulin and TSH receptor mRNA detection by RT-PCR in the follow-up of differentiated thyroid cancer patients.
    Torosian L; Manrique G; Alvarez B; Lago G; Roca R; Belzarena C
    Rev Esp Med Nucl; 2010; 29(3):109-13. PubMed ID: 20399540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.
    Milas M; Barbosa GF; Mitchell J; Berber E; Siperstein A; Gupta M
    Ann Surg Oncol; 2009 Feb; 16(2):473-80. PubMed ID: 19015922
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma.
    Dadparvar S; Krishna L; Brady LW; Slizofski WJ; Brown SJ; Chevres A; Micaily B
    Cancer; 1993 Jun; 71(11):3767-73. PubMed ID: 8490927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined analysis of circulating epithelial cells and serum thyroglobulin for distinguishing disease status of the patients with papillary thyroid carcinoma.
    Lin HC; Liou MJ; Hsu HL; Hsieh JC; Chen YA; Tseng CP; Lin JD
    Oncotarget; 2016 Mar; 7(13):17242-53. PubMed ID: 26684026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Serum thyroglobulin and whole-body scanning as markers in the follow-up of differentiated thyroid carcinomas].
    Degrossi OJ; Rozados IB; Damilano S; Degrossi EB; de Ganino L; Pinkas M; García del Río H; Artagaveytía D
    Medicina (B Aires); 1991; 51(4):291-5. PubMed ID: 1821916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The significance of thyroglobulin determination in the follow-up of patients with papillary or follicular thyroid carcinoma].
    Hennemann G; Hennemann IP; Docter R; Krenning EP
    Ned Tijdschr Geneeskd; 1989 Mar; 133(10):491-3. PubMed ID: 2651932
    [No Abstract]   [Full Text] [Related]  

  • 52. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
    Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
    Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
    Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation.
    Angell TE; Spencer CA; Rubino BD; Nicoloff JT; LoPresti JS
    Thyroid; 2014 Jul; 24(7):1127-33. PubMed ID: 24697314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of a new highly sensitive immunometric assay for thyroglobulin with reduced interference from autoantibodies.
    Broughton MN; Nome R; Sandven I; Paus E; Bjøro T
    Tumour Biol; 2016 Jun; 37(6):7729-39. PubMed ID: 26695140
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic
    Trevizam PG; Tagliarini JV; Castilho EC; de Alencar Marques M; Kiy Y; Mazeto GMFS
    Endocr Res; 2017 Feb; 42(1):42-48. PubMed ID: 27144920
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum thyroglobulin as a preclinical tumour marker in subgroups of thyroid cancer.
    Thoresen SO; Myking O; Glattre E; Rootwelt K; Andersen A; Foss OP
    Br J Cancer; 1988 Jan; 57(1):105-8. PubMed ID: 3348941
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation of thyroid fine-needle aspiration with final histopathology: a case series.
    Gürkan Dumlu E; Kiyak G; Bozkurt B; Tokaç M; Polat B; Cakir B; Güler G; Kiliç M
    Minerva Chir; 2013 Apr; 68(2):191-7. PubMed ID: 23612233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.